SP238THE EFFECT OF SELENIUM ON PREVENTION OF ACUTE KIDNEY INJURY AFTER ON-PUMP CARDIAC SURGERY

Abstract

INTRODUCTION AND AIMS: Cardiac surgery‐associated acute kidney injury (CSAAKI) is a frequent complication among patients who suffer from heart diseases. To our knowledge,AKI affects the outcome of cardiac surgeries. Also, Selenium has important influences on renal function. Therefore, the present study was performed to investigate the effect of Selenium on the prevention of CSA‐AKI. METHODS: In a randomized double‐blind placebo‐controlled trial, 120 patients consisting of 46 males and 74 females with the mean age of 52.8±16.7 years, whom had undergone elective on‐pump cardiac surgery. Patients were divided into two groups of 60 patients each: Selenium (case) group and placebo group. The case group received two doses of 500 mg Selenium orally,14 and 2 hours before surgery. The control group received only the standard care. The following tests were performed daily:arterial boold gasometry,creatinine,BUN,Albumin,electrolytes and lactate. The RIFLE and AKIN criteria were used to diagnose AKI RESULTS: There was not any significant difference in the mean score of European System for Cardiac Operative Risk Evaluation(EuroSCORE) between Se and placebo groups(1.3860.7 Vs. 1.3060.6, respectively; P=0.15).Based on the RIFLEcriteria,AKI was demonstrated to occur in 11(17.9%) patients from Se group and 13(21.4%) patients from placebo group(P=0.73),with the highest rate of AKI reported on the third and fourth post‐operative days in both groups. Furthermore, there was not any significant differences in the frequency of the patients were in the risk, injury,and failure stages, between groups, respectively (P=0.64).Also, according to the AKIN criteria, 28.8% and 35.7% patients in Se and placebo group developed AKI and were only in the first stage (P=0.55).The mean length of stay in ICU was 2.5361.07 days, and only one case of ICU mortality occurred CONCLUSIONS: The results of the present study showed that 500 microgram of oral Se was safe with no side effects, but did not support the superiority of this treatment as an anti‐inflammatory agent in on‐pump CABG surgery. We hope that the present findings underlie new studies in the future.